Abstract:Objectives To establish a mouse model of persistent tuberculosis involving Mycobacterium tuberculosis with different levels of virulence and to study the characteristics of that infection in order to lay a new foundation for the assessment and study of new vaccines and drugs against tuberculosis.Methods Female BALB/c mice were intravenously infected via the tail vein with 5 × 104 colony-forming units (CFUs) of the H37Rv standard virulent strain,the H37Ra strain,or the BCG vaccine strain of M.tuberculosis.Four and 8 weeks after infection,changes in the general status of mice and their weight were observed.Samples of lung and spleen tissues from infected mice were collected for histopathologic examination after HE staining.Mouse sera were tested for the titer of antibodies against M.tuberculosis using ELISA.Splenic lymphocytes of infected mice were isolated for an MTS assay of lymphocyte proliferation,and Th1/Th2 cytokines were detected with ELISA.The bacterial load in the spleen and lungs was determined by counting colony-forming units (CFUs) on 7H10 plates.Results There were no significant differences in the weight of mice 8 weeks after infection with strains that had differing levels of virulence.Macroscopic splenomegaly was observed in mice infected with H37Rv.Pathological lesions occurred in all infected mice according to histopathological slices.Four weeks after infection,Mycobacterium-specific antibodies were detected,and the antibody titer in infected mice did not differ significantly.The proliferation of spleen lymphocytes and the production of Th1/Th2 cytokines increased significantly in mice infected with H37Ra and mice infected with H37Rv.Four weeks after infection,the production of IFN-γ and IL-10 increased significantly in mice infected with H37Rv (P＜0.05).The bacterial load in the spleen of mice infected with H37Rv increased to 4.389±0.1245 log10 CFU,which was significantly higher than the load in mice infected with BCG (P＜0.05).The bacterial load in mice infected with H37Ra was 4.068±0.2184 log10 CFU,but the load did not differ significantly between mice infected with H37Ra and mice infected with BCG.There were no differences in the bacterial load in the lungs of the 3 infected groups.Eight weeks after infection,the bacterial load in the spleen of mice infected with H37Ra and mice infected with H37Rv increased significantly in comparison to that in mice infected with BCG (P＜0.05),but the bacterial load in the lungs did not differ among the 3 groups.The bacterial load in organs remained the same for at least 8 weeks,indicating a persistent infection.Conclusion A mouse model of persistent tuberculosis was successfully established and the characteristics of that infection were studied.This work will provide a useful animal model for further research and development of new vaccines and drugs against tuberculosis.

Therapeutic Efficacy of a Recombinant Mycobacterium Smegmatis Expressing Anhbha and Hil12 Fusion Protein Against Mycobacterium Tuberculosis Infection Induced in Mice

Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice.

Immune Responses and Protection Induced by a Recombinant Mycobacterium smegmatis Expressing an HBHA and hIL-12 Fusion Protein Against M.tuberculosis Infection

Enhancement Of Antituberculosis Immunity In A Humanized Model System By A Novel Virus-Vectored Respiratory Mucosal Vaccine

The Evaluation of Recombinant HBHA Vaccine by Mice Model Infected with Mycobacterium Tuberculosis

Immunotherapeutic Efficacy of Recombinantmycobacterium Smegmatisexpressing Ag85B–ESAT6 Fusion Protein Against Persistent Tuberculosis Infection in Mice

Construction and Identification of Recombinant Mycobacterium Smegmatis Which Expressing Fusion Gene of Heparin-Binding Haemagglutinin and Human IL12

Gls/Il-12-Modified Mycobacterium Smegmatis As A Novel Anti-Tuberculosis Immunotherapeutic Vaccine

Recombinant M. Smegmatis Vaccine Targeted Delivering IL-12/GLS into Macrophages Can Induce Specific Cellular Immunity Against M. Tuberculosis in BALB/c Mice

Therapeutic Efficacy of Micrococcus Luteus Rpf Domain and its Mutants against Mycobacterium Tuberculosis in Mice

The effect of immunization by recombinant Mycobacterium smegmatis encoding GLS and IL-12 in mice

Assessment of Recombinant Plasmid Expressing Fusion Antigen Ag85B-Rv3425 in Management of Acute Tuberculosis Infection in Mice.

Immune Response Elicited by Recombinant Mycobacterium smegmatis Expressed HBV Fused Gene in Mice in vivo

Immunogenicity and Protective Efficacy of a Fusion Protein Vaccine Consisting of Antigen Ag85B and HspX Against Mycobacterium Tuberculosis Infection in Mice

Evaluation of Immunotherapy Efficacy of M. Smegmatis and Vaccae in Murine Model of M. Tuberculosis Infection

Establishment of mouse models of persistent tuberculosis and characteristics of that infection

The Development and Preliminary Evaluation of a Newmycobacterium Tuberculosisvaccine Comprising Ag85b, HspX and CFP-10:ESAT-6 Fusion Protein with CpG DNA and Aluminum Hydroxide Adjuvants

Ag85B with C-Di-amp As Mucosal Adjuvant Showed Immunotherapeutic Effects on Persistent Mycobacterium Tuberculosis Infection in Mice

Immunogenicity and Protective Efficacy of a DNA Vaccine Encoding the Fusion Protein of Mycobacterium Heat Shock Protein 65(hsp65) with Human Interleukin‐2 Against Mycobacterium Tuberculosis in BALB/c Mice

Establishment of a mouse model of infection with rifampicin-resistant Mycobacterium tuberculosis

Efficient Tuberculosis Treatment in Mice Using Chemotherapy and Immunotherapy with the Combined DNA Vaccine Encoding Ag85B, MPT-64 and MPT-83